Ongoing genomic surveillance shows SARS-CoV-2 continuing to evolve mainly through Omicron sublineages such as BA.3.2 and XFG, which remain classified as variants under monitoring rather than variants of concern. These strains carry notable spike-protein mutations that could influence immune escape, yet current data indicate no substantial rise in severity, hospitalization rates, or vaccine evasion beyond levels already addressed by updated formulations. Health authorities continue routine tracking with wastewater sampling and traveler-based sequencing, and overall case incidence stays low without triggering new public-health alerts. This steady pattern of contained circulation underpins trader consensus that a fresh variant of concern is unlikely to emerge before 2027, though any unexpected surge in transmissibility could still shift assessments.